Cybin (NYSE:CYBN – Get Free Report) is one of 1,013 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Cybin to similar companies based on the strength of its valuation, profitability, dividends, analyst recommendations, risk, institutional ownership and earnings.
Risk & Volatility
Cybin has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Cybin’s rivals have a beta of 0.81, meaning that their average stock price is 19% less volatile than the S&P 500.
Valuation and Earnings
This table compares Cybin and its rivals gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Cybin | N/A | -$57.88 million | -48.90 |
Cybin Competitors | $2.17 billion | $157.25 million | -6.34 |
Insider and Institutional Ownership
17.9% of Cybin shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 15.0% of Cybin shares are owned by company insiders. Comparatively, 14.0% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Cybin and its rivals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Cybin | N/A | -42.36% | -40.56% |
Cybin Competitors | -3,692.96% | -259.74% | -31.83% |
Analyst Recommendations
This is a summary of current recommendations for Cybin and its rivals, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Cybin | 0 | 0 | 3 | 0 | 3.00 |
Cybin Competitors | 7180 | 19767 | 46142 | 1071 | 2.55 |
Cybin currently has a consensus price target of $50.50, suggesting a potential upside of 416.36%. As a group, “Pharmaceutical preparations” companies have a potential upside of 57.98%. Given Cybin’s stronger consensus rating and higher probable upside, equities analysts plainly believe Cybin is more favorable than its rivals.
Summary
Cybin rivals beat Cybin on 7 of the 13 factors compared.
Cybin Company Profile
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.